§ 01 Overview
Overview
Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide.
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
§ 02 Mechanism
Mechanism of action
Orforglipron binds the GLP-1 receptor as a non-peptide small molecule. Unlike oral semaglutide, it does not require a protective absorption enhancer or fasted administration.
- 01Convenient oral daily dosing
- 02Weight loss comparable to injectable GLP-1s in Phase II
- 03Potential for broader access given oral form
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 7 – 45 mg daily
- Starting Dose
- 3 mg daily
- Route
- Oral
- Timing
- Any time
- Frequency
- Daily
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
FDA Status
Investigational. Filed with FDA in 2025.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Wegovy Outperforms Orforglipron in Weight Loss Study - Precedence Research
Wegovy Outperforms Orforglipron in Weight Loss Study Precedence Research
Foundayo confers noninferior CV risk vs. insulin glargine for adults with type 2 diabetes - Healio
Foundayo confers noninferior CV risk vs. insulin glargine for adults with type 2 diabetes Healio
Lilly’s Orforglipron Meets CV Safety Endpoint, Shows Reduced Mortality Risk in Phase 3 ACHIEVE-4 Trial - BioPharm International
Lilly’s Orforglipron Meets CV Safety Endpoint, Shows Reduced Mortality Risk in Phase 3 ACHIEVE-4 Trial BioPharm International
ACHIEVE-4: Orforglipron Non-Inferior to Insulin Glargine for Cardiovascular Protection in T2D - HCPLive
ACHIEVE-4: Orforglipron Non-Inferior to Insulin Glargine for Cardiovascular Protection in T2D HCPLive
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health - Eli Lilly
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health Eli Lilly
Daily diabetes pill beats insulin on weight, A1C and heart safety - Stock Titan
Daily diabetes pill beats insulin on weight, A1C and heart safety Stock Titan
ACHIEVE-4: Orforglipron Meets CV Safety Endpoints in T2D and Obesity - MPR - Medical Professionals Reference
ACHIEVE-4: Orforglipron Meets CV Safety Endpoints in T2D and Obesity - MPR Medical Professionals Reference
Your Guide to Foundayo (orforglipron) for Weight Management - HealthCentral
Your Guide to Foundayo (orforglipron) for Weight Management HealthCentral
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02Diarrhea
- 03Constipation
Contraindications
None specified.